TY - JOUR
T1 - Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas
T2 - results of a phase-I study
AU - Goyal, Sagun
AU - Oak, Eunhye
AU - Luo, Jingqin
AU - Cashen, Amanda F.
AU - Carson, Kenneth
AU - Fehniger, Todd
AU - DiPersio, John
AU - Bartlett, Nancy L.
AU - Wagner-Johnston, Nina D.
N1 - Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Compared with solvent-based taxanes, nanoparticle albumin-bound (nab®) paclitaxel has demonstrated improved efficacy and tolerability in several solid tumor malignancies. Studies evaluating nab paclitaxel in patients with lymphoma are lacking. In this planned phase-I/phase-II study, we sought to determine the safety and efficacy of nab-paclitaxel in patients with relapsed/refractory (R/R) lymphoma. Eligible patients (R/R to ≥2 prior systemic therapies) received weekly nab-paclitaxel on days 1, 8 and 15 every 28 days. Dosing was initiated at 100 mg/m2 with dose escalations in 25 mg/m2 increments up to 150 mg/m2 in a classic 3 + 3 design. Twenty heavily pretreated patients (median 5 prior regimens), including 65% with refractory disease, enrolled. The maximum dose tested was well tolerated and grade 3/4 hematologic adverse events (neutropenia 25%, thrombocytopenia 20% and anemia 15%) were modest. The overall response rate was 10% with two partial responses, leading to a decision to close the study prematurely.
AB - Compared with solvent-based taxanes, nanoparticle albumin-bound (nab®) paclitaxel has demonstrated improved efficacy and tolerability in several solid tumor malignancies. Studies evaluating nab paclitaxel in patients with lymphoma are lacking. In this planned phase-I/phase-II study, we sought to determine the safety and efficacy of nab-paclitaxel in patients with relapsed/refractory (R/R) lymphoma. Eligible patients (R/R to ≥2 prior systemic therapies) received weekly nab-paclitaxel on days 1, 8 and 15 every 28 days. Dosing was initiated at 100 mg/m2 with dose escalations in 25 mg/m2 increments up to 150 mg/m2 in a classic 3 + 3 design. Twenty heavily pretreated patients (median 5 prior regimens), including 65% with refractory disease, enrolled. The maximum dose tested was well tolerated and grade 3/4 hematologic adverse events (neutropenia 25%, thrombocytopenia 20% and anemia 15%) were modest. The overall response rate was 10% with two partial responses, leading to a decision to close the study prematurely.
KW - Nab paclitaxel
KW - lymphoma and Hodgkin disease
KW - phase-1 study
KW - sparc
UR - http://www.scopus.com/inward/record.url?scp=85020663985&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1330954
DO - 10.1080/10428194.2017.1330954
M3 - Article
C2 - 28597723
AN - SCOPUS:85020663985
SN - 1042-8194
VL - 59
SP - 357
EP - 362
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 2
ER -